478 related articles for article (PubMed ID: 6225118)
21. Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria.
Holguin MH; Wilcox LA; Bernshaw NJ; Rosse WF; Parker CJ
J Clin Invest; 1989 Nov; 84(5):1387-94. PubMed ID: 2478585
[TBL] [Abstract][Full Text] [Related]
22. Characterization of the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes.
Parker CJ; Wiedmer T; Sims PJ; Rosse WF
J Clin Invest; 1985 Jun; 75(6):2074-84. PubMed ID: 4008653
[TBL] [Abstract][Full Text] [Related]
23. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.
Ross GD; Yount WJ; Walport MJ; Winfield JB; Parker CJ; Fuller CR; Taylor RP; Myones BL; Lachmann PJ
J Immunol; 1985 Sep; 135(3):2005-14. PubMed ID: 4020137
[TBL] [Abstract][Full Text] [Related]
24. [Immunocytochemical staining of decay-accelerating factor (DAF) on erythrocytes: paroxysmal nocturnal hemoglobinuria (PNH)].
Kobayashi T; Nakazawa M; Sato Y; Tomiyama J; Ninomiya H; Abe T; Terasawa T; Shichishima T; Fujita T
Rinsho Ketsueki; 1992 Feb; 33(2):162-6. PubMed ID: 1378912
[TBL] [Abstract][Full Text] [Related]
25. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack.
Miwa T; Zhou L; Hilliard B; Molina H; Song WC
Blood; 2002 May; 99(10):3707-16. PubMed ID: 11986227
[TBL] [Abstract][Full Text] [Related]
26. Proteolytic elimination of decay-accelerating factor (DAF): lytic abnormality coincides with removal of DAF in papain-treated human erythrocytes.
Seya T; Inoue H; Okada M; Matsumoto M; Kitamura H; Kinoshita T; Akedo H
Mol Immunol; 1990 Jan; 27(1):69-78. PubMed ID: 1690349
[TBL] [Abstract][Full Text] [Related]
27. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria.
Kinoshita T; Medof ME; Silber R; Nussenzweig V
J Exp Med; 1985 Jul; 162(1):75-92. PubMed ID: 2409211
[TBL] [Abstract][Full Text] [Related]
28. Decay-accelerating factor is present on paroxysmal nocturnal hemoglobinuria erythroid progenitors and lost during erythropoiesis in vitro.
Moore JG; Frank MM; Müller-Eberhard HJ; Young NS
J Exp Med; 1985 Oct; 162(4):1182-92. PubMed ID: 2413153
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of complement-mediated lysis of dithiothreitol-treated erythrocytes involves increased C9 insertion and polymerization.
Hu VW; Mazorow DL; Nicholson-Weller A; Shin ML
Mol Immunol; 1987 Aug; 24(8):887-96. PubMed ID: 2821389
[TBL] [Abstract][Full Text] [Related]
30. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
31. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting.
Sun X; Funk CD; Deng C; Sahu A; Lambris JD; Song WC
Proc Natl Acad Sci U S A; 1999 Jan; 96(2):628-33. PubMed ID: 9892684
[TBL] [Abstract][Full Text] [Related]
32. Deficiency of the homologous restriction factor in paroxysmal nocturnal hemoglobinuria.
Zalman LS; Wood LM; Frank MM; Müller-Eberhard HJ
J Exp Med; 1987 Feb; 165(2):572-7. PubMed ID: 2434597
[TBL] [Abstract][Full Text] [Related]
33. Studies on the sensitivity to complement-mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor).
Merry AH; Rawlinson VI; Uchikawa M; Daha MR; Sim RB
Br J Haematol; 1989 Oct; 73(2):248-53. PubMed ID: 2479410
[TBL] [Abstract][Full Text] [Related]
34. [Altered metabolism of membrane glycosphingolipids in erythrocytes of paroxysmal nocturnal hemoglobinuria].
Nakakuma H; Kawaguchi T
Rinsho Ketsueki; 1991 Jun; 32(6):606-11. PubMed ID: 1890736
[TBL] [Abstract][Full Text] [Related]
35. Paroxysmal nocturnal hemoglobinuria type III. Lack of an erythrocyte membrane protein restricting the lysis by C5b-9.
Hänsch GM; Schönermark S; Roelcke D
J Clin Invest; 1987 Jul; 80(1):7-12. PubMed ID: 3597779
[TBL] [Abstract][Full Text] [Related]
36. Regulation of the C3 nephritic factor stabilized C3/C5 convertase of complement by purified human erythrocyte C3b receptor.
Daha MR; Kok DJ; Van Es LA
Clin Exp Immunol; 1982 Oct; 50(1):209-14. PubMed ID: 6216999
[TBL] [Abstract][Full Text] [Related]
37. [Dysfunction and deficiency of decay-accelerating factor (DAF) demonstrated in the lymphocytes from a patient with paroxysmal nocturnal hemoglobinuria (PNH)].
Tomiyama J; Ninomiya H; Nakazawa M; Nagasawa T; Yoda Y; Abe T
Rinsho Ketsueki; 1989 Jun; 30(6):845-9. PubMed ID: 2477566
[TBL] [Abstract][Full Text] [Related]
38. Altered expression of gangliosides in erythrocytes of paroxysmal nocturnal hemoglobinuria.
Nakakuma H; Kawaguchi T; Horikawa K; Hidaka M; Yonemura Y; Kawakita M; Kagimoto T; Iwamori M; Nagai Y; Takatsuki K
J Clin Invest; 1990 May; 85(5):1456-61. PubMed ID: 2185273
[TBL] [Abstract][Full Text] [Related]
39. T-lymphocytes escape membrane defect in paroxysmal nocturnal haemoglobinuria.
Cooper MR; Currie MS; Rustagi PK; Logue GL
Br J Haematol; 1983 Oct; 55(2):263-71. PubMed ID: 6604541
[TBL] [Abstract][Full Text] [Related]
40. Deficiency of glycosyl-phosphatidylinositol anchored proteins on paroxysmal nocturnal haemoglobinuria (PNH) neutrophils and monocytes: heterogeneous deficiency of decay-accelerating factor (DAF) and CD16 on PNH neutrophils.
Kawakami Z; Ninomiya H; Tomiyama J; Abe T
Br J Haematol; 1990 Apr; 74(4):508-13. PubMed ID: 1693286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
